Status:
COMPLETED
The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis
Lead Sponsor:
Shanghai Changzheng Hospital
Collaborating Sponsors:
Ningbo No. 1 Hospital
The First Affiliated Hospital of Soochow University
Conditions:
Healthy People
Benign Prostatic Hyperplasia
Eligibility:
MALE
18-80 years
Brief Summary
Prostate-specific antigen (PSA) testing has limited specificity for prostate cancer diagnosis, leading to a high rate of unnecessary biopsies. This multi-center study aims to develop and validate a no...
Detailed Description
Prostate cancer is a leading cause of cancer morbidity in men globally. The current diagnostic pathway, heavily reliant on PSA levels, is particularly challenging in the 4-10 ng/mL "gray zone," where ...
Eligibility Criteria
Inclusion
- Men aged 18-80 years with a clinical indication for prostate or pelvic magnetic resonance (MR) examination.
- Patients with normal prostate, benign prostatic hyperplasia, or prostate cancer.
- First visit on January 1, 2014, or later.
Exclusion
- Diagnosis of any other malignancy within the previous 5 years.
- Prior transurethral resection or enucleation of the prostate before imaging.
- Any condition deemed by the investigator to make the patient unsuitable for study participation.
Key Trial Info
Start Date :
October 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2025
Estimated Enrollment :
1651 Patients enrolled
Trial Details
Trial ID
NCT06589154
Start Date
October 10 2024
End Date
July 30 2025
Last Update
September 2 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
2
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510120
3
Jiangsu Provincial People's Hospita
Nanjing, Jiangsu, China, 210029
4
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, China